Development of [F-18]-Labeled Amyloid Imaging Agents for PET

Mathis, CA

关键词: BRAIN;    DESIGN;    DISEASES;    HYPOTHESIS;    IN VITRO;    IN VIVO;    POSITRONS;    RADIOPHARMACEUTICALS;    TESTING;    TOMOGRAPHY radiopharmaceutical positron emission tomography PET F-18 amyloid amyloid imaging;   

DOI  :  10.2172/903085
RP-ID  :  DOE/ER/63590
PID  :  OSTI ID: 903085
Others  :  Other: ID: ER63590-1021311-0009485
Others  :  TRN: US1002546

学科分类：放射科、核医学、医学影像

美国|英语

来源: SciTech Connect

【 摘 要 】

The applicant proposes to design and synthesize a series of fluorine-18-labeled radiopharmaceuticals to be used as amyloid imaging agents for positron emission tomography (PET). The investigators will conduct comprehensive iterative in vitro and in vivo studies based upon well defined acceptance criteria in order to identify lead agents suitable for human studies. The long term goals are to apply the selected radiotracers as potential diagnostic agents of Alzheimer's disease (AD), as surrogate markers of amyloid in the brain to determine the efficacy of anti-amyloid therapeutic drugs, and as tools to help address basic scientific questions regarding the progression of the neuropathology of AD, such as testing the "amyloid cascade hypothesis" which holds that amyloid accumulation is the primary cause of AD.